ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 595,48
0,61%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cellectar Biosciences Inc (CLRBW)

  7. Cellectar Biosciences Inc (CLRBW) Actualités

CLRBW

Cellectar Biosciences (CLRBW)

Cellectar Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CLRBW
DateHeureSourceTitreSymboleSociété
07/01/201914h30GlobeNewswire Inc.Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBWCellectar Biosciences Inc
03/01/201914h30GlobeNewswire Inc.Cellectar Biosciences to Present at the Biotech ShowcaseNASDAQ:CLRBWCellectar Biosciences Inc
11/12/201814h30GlobeNewswire Inc.Cellectar Granted Japanese Patent for CLR 131NASDAQ:CLRBWCellectar Biosciences Inc
04/12/201814h30GlobeNewswire Inc.Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBWCellectar Biosciences Inc
13/11/201814h30GlobeNewswire Inc.Cellectar Reports Third Quarter 2018 Financial Results and Provides Business UpdateNASDAQ:CLRBWCellectar Biosciences Inc
12/11/201814h30GlobeNewswire Inc.Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology StudiesNASDAQ:CLRBWCellectar Biosciences Inc
02/10/201814h00GlobeNewswire Inc.Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...NASDAQ:CLRBWCellectar Biosciences Inc
27/09/201814h30GlobeNewswire Inc.Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceNASDAQ:CLRBWCellectar Biosciences Inc
25/09/201814h30GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric OsteosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
24/09/201814h00GlobeNewswire Inc.Cellectar Biosciences Provides an Update on the FDA Import AlertNASDAQ:CLRBWCellectar Biosciences Inc
17/09/201814h30GlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of OsteosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
29/08/201814h30GlobeNewswire Inc.Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:CLRBWCellectar Biosciences Inc
20/08/201814h30GlobeNewswire Inc.Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma PatientsNASDAQ:CLRBWCellectar Biosciences Inc
13/08/201814h00GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s SarcomaNASDAQ:CLRBWCellectar Biosciences Inc
10/08/201814h00GlobeNewswire Inc.Cellectar Reports 2018 Second Quarter Financial Results and Provides Business UpdateNASDAQ:CLRBWCellectar Biosciences Inc
01/08/201814h30GlobeNewswire Inc.Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug ConjugateNASDAQ:CLRBWCellectar Biosciences Inc
31/07/201822h05GlobeNewswire Inc.Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Op...NASDAQ:CLRBWCellectar Biosciences Inc
27/07/201814h30GlobeNewswire Inc.Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering NASDAQ:CLRBWCellectar Biosciences Inc
18/07/201814h00GlobeNewswire Inc.Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL PatientsNASDAQ:CLRBWCellectar Biosciences Inc
17/07/201814h00GlobeNewswire Inc.Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical ...NASDAQ:CLRBWCellectar Biosciences Inc
13/07/201822h05GlobeNewswire Inc.Cellectar Announces 1-for-10 Reverse Stock SplitNASDAQ:CLRBWCellectar Biosciences Inc
09/07/201814h00GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s SarcomaNASDAQ:CLRBWCellectar Biosciences Inc
28/06/201814h00GlobeNewswire Inc.Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 TrialNASDAQ:CLRBWCellectar Biosciences Inc
07/06/201814h30GlobeNewswire Inc.Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131NASDAQ:CLRBWCellectar Biosciences Inc
06/06/201814h00GlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of RhabdomyosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
11/05/201814h00GlobeNewswire Inc.Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial ResultsNASDAQ:CLRBWCellectar Biosciences Inc
09/05/201820h28GlobeNewswire Inc.Cellectar Granted Orphan Drug Designation for CLR 131 to Treat RhabdomyosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
02/05/201814h00GlobeNewswire Inc.Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat NeuroblastomaNASDAQ:CLRBWCellectar Biosciences Inc
17/04/201814h00GlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Mu...NASDAQ:CLRBWCellectar Biosciences Inc
16/04/201814h05GlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broa...NASDAQ:CLRBWCellectar Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:CLRBW

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
EU
GLE
Societe Generale
EU
RI
Pernod Ricard
NASDAQ
AAPL
Apple
EU
CAP
Capgemini
EU
BEL20
Bel 20
EU
BN
Danone
NYSE
MRK
Merck
SPI
SP500
S&P 500
NASDAQ
GOOGL
Alphabet
NASDAQ
MSFT
Microsoft
COIN
BTCUSD
Bitcoin
EU
EN
Bouygues
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés